Yeah I got a similar email from her a few months back too. I remember I was curious about her thoughts on it.
She is doing the peer review, Neuromod has this disclosed on their website for sometime now, it's in the Phase IIb protocol document (
https://www.lenire.com/clinical-studies). Yes the tricky part for them is the lack of a placebo group, which is exactly what Dr. Shore is hinting on. But with evidence of control through another method, in this case the results 12 months after treatment (long after any placebo would have worn off) this probably won't be too big of an issue. This appears to be the main thing Dr. Shore wants to scrutinize, which I think is a very good thing.
Though I agree they should have used a control group for one of the arms, when they already know a method works, I also kind of like that they used more randomized arms to evaluate which settings work best. I'm not exactly sure why they didn't choose to not do a placebo group, but I could imagine it's because they wanted to have as many participants as possible to try out the different settings and thus better find which is optimal.